Diabète post-transplantation rénale: le point de vue du diabétologue [Post-transplantation diabetes in kidney transplant: from the diabetologist point of view]
Fiche du document
10 juin 2020
- doi: 10.53738/REVMED.2020.16.697.1200
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.697.1200
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32520459
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_77E6105192BB7
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Type 1 diabetes Brittle diabetes IDDM (Disease) Ketosis prone diabetes Diabetes mellitus Insulin-dependent diabetesCiter ce document
A. Pauchet et al., « Diabète post-transplantation rénale: le point de vue du diabétologue [Post-transplantation diabetes in kidney transplant: from the diabetologist point of view] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.697.1200
Métriques
Partage / Export
Résumé
Post-transplantation diabetes (PTDM) exposes to increased morbidity (cardiovascular or infectious complications, early graft dysfunction) and to a risk of premature death. Recognition of risk factors is essential for early and individualized care. The management of a PTDM requires the use of oral antidiabetic treatments (metformin or DPP4 inhibitors) or GLP1 receptor agonists for their favorable effects on weight and kidney that seem ideal in this context. Corticosteroid-induced diabetes or the rare occurrence of diabetic ketoacidosis require insulin therapy. In the long term, the main objective remains to integrate PTDM treatment in a more comprehensive management, targeting the reduction of cardiovascular risk of vulnerable transplant patients.